Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, Buti, Sebastiano · 2019 · Clinical Lung Cancer

Abstract

BACKGROUND Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC). METHODS Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Univariate and multivariate analyses were performed to evaluate the relationships between types of irAEs (differentiated according to system/organ involved and to single-site/multiple-site), overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). We further performed a 6-week landmark analysis. RESULTS A total of 559 patients were enrolled; 231 patients (41.3%) developed irAEs of any grade and 50 patients (8.9%) G3/G4 events; 191 of them (82.6%) developed "single-site" irAEs and 40 (17.4%) "multiple-site" irAEs. At multivariate analysis, higher ORR was related to irAEs of any grade (P < .0001), "single-site" irAEs (P < .0001), endocrine (P = .0043) and skin irAEs (P = .0005). Longer PFS was related to irAEs of any grade (P < .0001), "single-site" irAEs (P < .0001), "multiple-site" irAEs (P = .0374), endocrine irAEs (P = .0084) and skin irAEs (P = .0001). Longer OS was related to irAEs of any grade (P < .0001), "single-site" irAEs (P < .0001), endocrine irAEs (P = .0044), gastrointestinal irAEs (P = .0437), skin irAEs (P = .0006), and others irAEs (P = .0378). At the 6-week landmark analysis, irAEs of any grade was confirmed an independent predictor of higher ORR, longer PFS, and longer OS. CONCLUSION Our study confirmed that irAEs are concordantly related to higher ORR, longer PFS, and longer OS with anti-PD-1 immunotherapy in patients with NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2019.02.006

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 178

Metadata

Authors
Cortellini, A., Chiari, R., Ricciuti, B., Metro, G., Perrone, F., Tiseo, M., Bersanelli, M., Bordi, P., Santini, D., Giusti, R., Grassadonia, A., Di Marino, P., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Malorgio, F., Garufi, C., Russano, M., Anesi, C., Zeppola, T., Filetti, M., Marchetti, P., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Iacono, D., Migliorino, M. R., Porzio, G., Cannita, K., Ficorella, C., & Buti, S.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2019-07
Volume
20
Issue
4
Pages
237-247.e1
ISSN
1525-7304 (ISSN-L)
OpenAlex
W2917602796
Cited by
178
References
8
FWCI
8.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.